Research Progress on Prognostic Factors of Multiple Myeloma--Review.
10.19746/j.cnki.issn.1009-2137.2021.04.053
- Author:
Ke-Wa MA
1
;
Chao SUN
1
;
Jian-Yong LI
2
;
Xin ZHOU
3
Author Information
1. Department of Hematology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi 214023, Jiangsu Province, China.
2. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
3. Department of Hematology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi 214023, Jiangsu Province, China,E-mail: zx89232@126.com.
- Publication Type:Review
- MeSH:
Humans;
Multiple Myeloma;
Neoplasm, Residual;
Prognosis;
Quality of Life
- From:
Journal of Experimental Hematology
2021;29(4):1346-1350
- CountryChina
- Language:Chinese
-
Abstract:
At present, multiple myeloma (MM) still can not be cured, so it is particularly important to study the prognostic factors of MM. Recently, based on the characteristics of tumor or host, the complete disease staging systems, such as Mayor mSMART and frailty scoring system have been updated. Other independent prognostic factors, such as minimal residual disease, circulating tumor DNA, red blood cell distribution width, lymphocyte ratio and thymidine kinase 1 are of great value in evaluating the prognosis of MM from different perspectives. The comprehensive study about these prognostic factors is helpful to identify patients with high-risk MM to guide treatment and hopefully improves the quality of life of patients. In this review, the latest research progress of prognostic factors for MM is summarized briefly.
